1. SARS-Cov-2 and COVID-19 a new pandemic {#sec0001}
=========================================

COVID-19 is the pandemic disease caused by severe acute respiratory syndrome (SARS) coronavirus two (SARS-CoV-2) infection ([@bib0183]a; [@bib0181]). About 80% of people infected with SARS-CoV-2 develop a self-limiting illness, 20% require hospitalisation, largely due to cardiovascular issues and about 5% require critical care and potential ventilatory support ([@bib0085]; [@bib0043]). The mortality in those requiring ventilatory support is about 40--50% ([@bib0161]; [@bib0182]b). Death from COVID-19 is associated with older age and comorbidities such as cardiovascular disease, smoking, lung disease, obesity and diabetes ([@bib0183]a; [@bib0100]; [@bib0127]). Mortality in young people and those without comorbidities may be related to excessive viral load ([@bib0097]a; [@bib0027]a). Whilst the typical clinical features requiring self-isolation, and potentially hospitalization are fever, dry cough and shortness of breath related to respiratory tract infection, other symptoms such as headache and gastrointestinal symptoms may go unnoticed or under-appreciated leading to spreading of the virus ([@bib0182]b; [@bib0127]; [@bib0076]). People shed infective virus days before symptoms occur and continue to shed virus via the lungs and faeces whilst symptoms develop and resolve, often for more than 7 days after symptom onset ([@bib0091]; [@bib0168]a; [@bib0067]a).

SARS-CoV-2 is a betacoronavirus closely-related to virus that caused the SARS outbreak in 2002-2004 ([@bib0181]). The viral ribonucleic acid (RNA) is bound by the nucleocapsid protein and is encapsulated in a host cell membrane-derived lipid envelope containing the viral spike, envelope and membrane proteins ([@bib0031]b, [@bib0101]). The spike protein contains the receptor binding domain (RBD), which is important for binding to the angiotensin converting enzyme two (ACE2) cell receptor, and thus key to the cellular target, host range and viral infection ([@bib0181]; [@bib0118]; [@bib0138]. [Fig. 1](#fig0001){ref-type="fig"} ). Viral ACE2 binding is facilitated by host cell, serine proteases such as TMPRSS2 necessary to prime the spike protein ([@bib0074]; [@bib0147]). The ACE2 receptor is expressed on the vasculature and is present in many tissues, such as the kidney, gut, cardiomyocytes and lung epithelia ([@bib0063]; [@bib0102]). There is very low expression of ACE2 on immune cells, but other co-receptors, including: CD147, proteases and probably lectins, based on similarities with the SARS-CoV virus, may be important in SARS-CoV-2 entry ([@bib0093]; [@bib0171]; [@bib0158]a; [@bib0060]).Fig. 1The protective and destructive immune response against the SARS-CoV-2 virus.Immune cells target the SARS-CoV-2 virus that initially involves the innate immune response, which is then supplemented with anti-viral cytotoxic T cell responses and neutralizing and binding antibodies.Fig 1

2. Multiple sclerosis in the COVID-19 era {#sec0002}
=========================================

The immune system provides vital defence against viral infections. This has led to concern for people taking immunosuppressive agents, as immune compromised people are particularly vulnerable to infection ([@bib0036]; [@bib0163]; [@bib0103]). Infections are more common in people taking DMT and are more frequent with the higher efficacy drugs ([@bib0163]; [@bib0103]). This is consistent with their more potent immunosuppressive activities. Immunosuppressed people have been advised to self-shield and socially distance themselves to avoid infection and will remain a problem, until herd immunity, anti-viral agents or effective vaccines have been developed ([@bib0089]; [@bib0141]). Multiple sclerosis (MS) is a major neurological disease that causes disability and can require hospitalisation for uncontrolled disease activity ([@bib0039]). MS is currently managed with immunomodulatory drugs ([@bib0120]). This has led neurologists to recommend maintaining the *status quo* or curtailing the use of certain disease modifying treatments (DMT) in a pragmatic or non-pragmatic way ([@bib0036], [@bib0057]; [@bib0019]. [Table 1](#tbl0001){ref-type="table"} ). It is understandable that a conservative "primum non nocere" (first do not harm) approach was adopted when considering treatments, given the paucity of knowledge surrounding SARS-CoV2 biology when COVID-19 first emerged. However, it is important to recognize the risks of poorly controlled MS may outweigh the perceived risks from COVID-19 ([@bib0057]; [@bib0019]) and an essential goal of MS care must be to limit SARS-CoV-2 infection. Therefore, care must be to prevent disease activation and limit the need for hospitalization that could potentially increase the risk of exposure to SARS-CoV-2. This must be balanced by the requirement of hospitalization for infusion treatments and the level of monitoring that each agent requires, that is particularly arduous with alemtuzumab, but minimal with ocrelizumab and glatiramer acetate ([@bib0120]).Table 1Initial recommendations use of MS-related DMT by some European neurological associations.Table 1Summary of SIN/ABN GuidelinesAt risk categoryClassTrade NameSafe to start treatmentOn treatmentCOVID-19 infectionMode of actionLowInterferon-betaBetaferon, Avonex, Rebif, PlegridyYESCONTINUESTOPImmunomodulatory (not immunosuppressive), pleiotropic immune effectsLowGlatiramer acetateCopaxoneYESCONTINUESTOPImmunomodulatoy (not immunosuppressive), pleiotropic immune effectsLowTeriflunomideAubagioYESCONTINUESTOPDihydro-orotate dehydrogenase inhibitor (reduced de novo pyrimidine synthesis), anti-proliferativeLowDimethyl fumarateTecfideraYESCONTINUESTOPPleiotropic, NRF2 activation, downregulation of NFΚβLowNatalizumabTysabriYESCONTINUESTOPAnti-VLA4, selective adhesion molecule inhibitorLowS1P modulatorsFingolimod (Gilenya)YESCONTINUESTOPSelective S1P modulator, prevents egress of lymphocytes from lymph nodesIntermediateAnti-CD20Ocrelizumab (Ocrevus)NO (YES)SUSPENDDELAYAnti-CD20, B-cell depleterHigh[\*](#tb1fn1){ref-type="table-fn"}CladribineMavencladNOSUSPENDDELAYDeoxyadenosine (purine) analogue, adenosine deaminase inhibitor, selective T and B cell depletionHigh[\*](#tb1fn1){ref-type="table-fn"}AlemtuzumabLemtradaNOSUSPENDDELAYAnti-CD52, non-selective immune depleterHigh[\*](#tb1fn1){ref-type="table-fn"}HSCT-NO-DELAYNon-selective immune depleter[^1]

It is important that such recommendations about treatment are made on a rational basis using knowledge of the mode of actions of the various agents and their ability to impact on the functioning of the components of the immune system. This is important as there is no evidence that immunosuppressed people are at increased risk to coronavirus infections ([@bib0041]). Therefore, to understand the risks posed to people with MS using DMT, it is crucial to understand the mechanisms of action, the impact of the treatments on infection-risk, vaccination responses and the mechanisms of pathology and immunity to SARS-CoV-2. Although there are gaps in our knowledge, understanding can be gained from the study of SARS-CoV infection, as well as other coronaviruses and lower respiratory tract infections ([@bib0024]; [@bib0125]; [@bib0128], [@bib0134]).

3. Immune response against SARS-CoV-2 virus {#sec0003}
===========================================

Protection against coronaviruses involves both the innate and adaptive immunity, typical for most viral infections ([@bib0175]; [@bib0125]). However, consistent with SARS, some influenza infections and COVID-19, it appears to be the immune response and destruction of virally-infected cells and lung epithelial tissue that cause the acute respiratory distress syndromes (ARDS) and the, sometimes fatal, pneumonia ([@bib0031]b; [@bib0177]a). It appears that the immune response to SARS-CoV-2 occurs in two phases involving an immune and a tissue, often lung, damaging phase.

3.1. Immune phase {#sec0004}
-----------------

Following infection there is an asymptomatic period of 4--5 days, although some reports indicate this can be up to 3 weeks ([@bib0126], [@bib0091]; [@bib0090]), during which time the virus attempts to escape immune surveillance through the inhibition of interferon production and blockade of interferon receptor signalling activity, similar to SARS-CoV ([@bib0125]; [@bib0032]; [@bib0114]). There is an early immune response where the innate and then the adaptive immune response eliminates the virus as seen in non-human primates and by inference in humans ([@bib0015]; [@bib0150]). Given that the majority of infections are asymptomatic ([@bib0085]; [@bib0043]) indicates that this is a dominant mechanism in most people with COVID-19. *In vitro* data suggest an early innate response, notably from the alveolar macrophages and/or monocytes that may be recruited from the circulation ([@bib0175]; [@bib0150]). Histological studies of cancerous lungs of people subsequently positive for COVID19, exhibited significant macrophage activity ([@bib0021]; [@bib0148]a). Thus, macrophages rather than neutrophils appear to be important as an early defence mechanism in SARS and COVID-19 lesions ([@bib0125]; [@bib0148]a; [@bib0021]). This is probably followed by a CD8 cytotoxic T cell response that is generated within days of infection ([@bib0024]; [@bib0125]; [@bib0150]).

SARS-CoV-2 may be eliminated before significant blood antibody titres are generated as seen in non-human primate infections and case reports ([Fig.2](#fig0002){ref-type="fig"} . [@bib0150]; [@bib0015]; [@bib0140]). These antibody responses are generated around 12 days (IgM) and 14 days (IgG), although this is earlier in some individuals (Zhoa et al. 2020; [@bib0115]; [@bib0167]). Antibodies are predominantly generated against the nucleocapsid and spike proteins ([@bib0115]; [@bib0044]). Antibodies against the RBD of the spike protein are clearly neutralizing, are able to prevent infection ([@bib0115]; [@bib0147]; [@bib0149]b). These appear to be protective, as evidenced by the use of convalescent sera to protect against severe COVID-19 ([@bib0048]; [@bib0121]; [@bib0137]). People with X-linked agammaglobulinemia have been infected and survived COVID-19 ([@bib0140]). This further suggests that B cells and immunoglobulin may not be an obligate immune element required for protection against SARS-CoV-2 infection. Although CD8 T cells are important in viral immunity, antibodies will however, be an essential for the vaccination response to prevent primary infection and reinfection. Most infected subjects will develop an immunoglobulin anti-viral response within 1 month ([@bib0179], [@bib0115]; [@bib0044]). This appears to prevent re-infection as shown in non-human primates ([@bib0015]. [Fig. 2](#fig0002){ref-type="fig"}). However, immunity may not be completely protective since people with COVID-19 can rarely present with SARS-CoV-2 re-activation ([@bib0173]a; [@bib0025]c). However, as the virus may persist in many sites and may not be eliminated at the same rates ([@bib0029]d). This may in part explain why viral RNA is detected in faeces when nasopharyngeal swabs become negative ([@bib0029]d). There are clearly viral variants ([@bib0051]; [@bib0176]a) and may be important as vaccines will need to target disease-causing pathogenic variants. This data suggests that immunosuppression of macrophage function and probably CD8 activity may limit anti-viral protection, while blunting or inhibition of antibody formation may limit immunity to reinfection.Fig. 2*Removal of the SARS-CoV-2 virus occurs before a significant anti-viral antibody response is generated.* Rhesus macaques were infected with coronavirus and the viral titre was assessed using nasal swabs. Animals were re-infected one month later. The results show the responses of two individual (blue and orange) monkeys, as seen in two additional monkeys, relating to viral titre and anti-viral antibody response. A.U. arbitrary units. Adapted from [@bib0015]. DoI.org/10.1101/2020.03.13.990226Fig 2

3.2. Destructive phase {#sec0005}
----------------------

Although most people appear to tolerate COVID-19 a significant number of people experience respiratory distress ([@bib0026]e; [@bib0182]b). It has also been suggested that abnormal coagulation, pulmonary embolism, and endothelial dysfunction are other pathologies of severe COVID-19, which could in part be related to virus and inflammation-induced oxidative stress ([@bib0052]; [@bib0124]). However, severe disease is associated with peripheral blood neutrophilia and notably lymphopenia ([@bib0026]e, [@bib0099]b, [@bib0157]b), where viral load relates to the severity of lymphopenia ([@bib0098]c). The lymphopenia could relate to sequestration of cells into the infected tissues as part of the anti-viral response. Post-mortem histology demonstrates significant mononuclear infiltration into the lung and often, but not always, a paucity of natural killer cells and neutrophils, unless associated with secondary infection ([@bib0169]b; [@bib0052]; [@bib0170]b; [@bib0105]; Aurelio Sonzogni et al. 2020). There is a paucity of B cells and perhaps of relevance is that the lymphocytes are predominantly CD4 T cells ([@bib0169], [@bib0170]b). Low peripheral blood CD8 T cell numbers are a poor prognostic feature ([@bib0047]) consistent with a common feature of the COVID-19 lung pathology, where there is a paucity of CD8 T cells ([@bib0169], [@bib0170]b; [@bib0178]b). This may reflect senescence and exhaustion of the anti-viral CD8 response ([@bib0180]; [@bib0040]). Whether this contributes to severe disease and fatality remains to be established. However, this would be consistent with age being a major poor prognostic feature ([@bib0076]). It appears that T cells can be infected via CD147 ([@bib0159]c). In addition, infection and expression of envelope protein and Open Reading Frame protein sequestration that has been shown to have an apoptotic effect at least after SARS-CoV infection ([@bib0172]). This may play a role in the lymphopenia and immune suppression of the anti-viral response. There is marked atrophy of lymphoid tissues that may contribute to the lymphopenic state ([@bib0030]f; [@bib0178]b, [@bib0170]b). Macrophages may also become infected and can take-up the virus due to expression of CD147, lectins and Toll-like receptors known to recognize SARS-CoV pathogen associated molecular pattern recognition elements such as single stranded viral RNA or uptake of viral antibody complexes ([@bib0158]a; [@bib0171]; [@bib0094]; [@bib0078]). Macrophage activity may contribute to the lymphopenia ([@bib0030]f). Macrophage derived cytokines are produced, which lead to cytokines storms associated with worse prognosis ([@bib0025]c; [@bib0072]; [@bib0162]; [@bib0164]). Therefore, agents such as IL-6 receptor and IL-1 blockers used in rheumatoid arthritis, and the case of IL-6R off-label in neuromyelitis optica, are being used to limit severe COVID-19 ([@bib0104]). Plasma cell-supporting cytokines such as TNFSF13 may be associated with recovery ([@bib0162]), however, the antibody response may contribute to macrophage hyper-activation. As such, severe disease is associated with the highest titres of antibodies ([@bib0096]; [@bib0179]) and antibody-dependent enhancement of disease may occur ([@bib0078]). There is complement activation, vascular damage and microthrombi that develop, indicative of damage consistent with oxidative stress, IgG3 anti-viral responses and IgG antibody-dependent cellular cytotoxicity by macrophages and in some instance neutrophils ([@bib0105]; [@bib0178]b). Interestingly, it has been shown that spike-specific antibody may promote IL-8 and CCL2 production that skews macrophage accumulation towards a destructive phenotype ([@bib0096]). As such in other lower respiratory tract infections antibodies can sometimes have destructive potential ([@bib0084]), therefore immunomodulation during periods of lung damage may offer some benefit.

4. Mechanisms driving multiple sclerosis may be distinct from COVID-19 protection and pathogenesis {#sec0006}
==================================================================================================

Although it is widely considered that CD4, TH17 T cells are the central mediators of MS ([@bib0088]), all active DMT inhibit memory B cell activity in a hierarchical fashion that reflects their therapeutic activity ([@bib0120], Baker et al. 2017, [@bib0009]). This could be secondary to inhibition of T cell function ([@bib0132]a, [@bib0133]b). Targeting memory B cell subsets, and possibly CD4, Th17 T cells, is not likely to prevent SARS-CoV-2 elimination by CD8 T cells and the innate immune responses. This may only be relevant with continuous treatments that maintain peripheral B cells in a nadir state and prevent antibody secreting cell (ASC) formation ([@bib0132]a; [@bib0011]a). However, ASC can be generated by germinal centre cells independent of the CD27+, memory B cell pathway ([@bib0009]; [@bib0062]; [@bib0083]). Novel vaccine responses will be generated from the immature/naïve B cell compartments that regenerate most rapidly following B cell depleting therapies ([@bib0006]b, [@bib0010], [@bib0011]a). Once formed, anti-viral responses will reside within the long-lived plasma cell pool with lymphoid tissue and bone marrow ([@bib0083]; [@bib0009]). Plasma cells are relatively quiescent ([@bib0083]) and thus avoid the action of agents targeting proliferating cells and they also express low levels of CD52, deoxycytidine kinase and CD20 targeted by high-efficacy, depleting DMT ([@bib0012]b; [@bib0132]a, [@bib0010]). Furthermore, they reside predominantly in the bone marrow, a site that may not be effectively targeted by depleting antibodies as cell elimination requires entry of antibodies, complement components and effector accessory cells required for depletion ([@bib0009]). Thus once formed, plasma cells may not be particularly well targeted by the current DMT, except haematopoietic stem cell therapy (HSCT) that purges the lymphoid tissues. It will be important to consider how best to deliver a SARS-CoV-2 vaccine in the future ([@bib0002]; [@bib0028]). Strategies could be developed for the highly-active agents that accommodate the long-depletion of memory B cells and the more rapid population of naïve cells to allow a vaccination response against SARS-CoV-2 whilst maintaining protection against MS.

5. Low efficacy MS immunomodulators are unlikely to limit anti-viral immunity {#sec0007}
=============================================================================

The components of the immune response that drive autoimmunity and control infection use overlapping cellular mechanisms. Therefore, removal of significant immune subsets may have the capacity to reduce anti-viral responses in a manner that reflects their immunosuppressive potential. Low treatment-efficacy agents such as glatiramer acetate, beta interferons and teriflunomide ([Table 1](#tbl0001){ref-type="table"}) are not associated with significant immunosuppression, notable increased risk of viral infections, nor lack of responsiveness to vaccines ([@bib0120]; [@bib0038]a; [@bib0165]; [@bib0116]; [@bib0065]). Indeed, interferon beta and teriflunomide may have anti-viral activity that could be beneficial ([@bib0070]; [@bib0014]). As such beta interferon has been shown to inhibit SARS-CoV replication and is currently being trialled in COVID-19 ([@bib0042]; [@bib0070]; NCT04350671; NCT04343768). However, these agents have a downside in that they are not that effective in controlling MS disease activity.

6. Moderate efficacy MS immunomodulators carry higher, but modest infection risks {#sec0008}
=================================================================================

Dimethyl fumarate is modestly immunosuppressive and targets lymphocytes rather than monocytes ([@bib0120]; [@bib0045]). Immature/transitional B cells are less affected compared to memory B cell targeting ([@bib0108]). Although plasmablasts and plasma cells can be affected by dimethyl fumarate therapy ([@bib0108]), immunoglobulin levels are not unduly reduced ([@bib0045]). Importantly, vaccine responses in people on dimethyl fumarate were no different to those treated with beta interferons ([@bib0156]). However, in some individuals persistent lymphopenia has been reported ([@bib0108]; [@bib0045]), notably about 20% of people will exhibit CD8 T cell levels below the lower limit of normal ([@bib0108]). Although this is not generally associated with increased infection rates ([@bib0016]), viral infections, including upper respiratory and lung infections occur with the monomethyl fumarate producing compounds ([@bib0120]; [@bib0045]; [@bib0122]; [@bib0049]; [@bib0111]).

Functional lymphopenia occurs with sphingosine-1-phosphate receptor modulators such as fingolimod ([@bib0120]; [@bib0045]). This appears to modestly elevate efficacy and infection risks ([@bib0120]; [@bib0080]). These agents are reported to sequester lymphocytes within lymphoid tissues and exhibit limited activity on the innate immune response ([@bib0087]; [@bib0120]; [@bib0152]; [@bib0003]). Fingolimod targets CD4 more than CD8 T cells and notably the naïve and central memory T cell subsets to retain them in lymphoid tissues where anti-viral responses would be generated ([@bib0087]; [@bib0003]; [@bib0073]). It also exhibits a more modest decrease in effector memory CD4 and CD8 T cells that will enter inflamed tissues ([@bib0003]). Infections rates are modest ([@bib0045]), but some bacterial and viral, infections such as herpes and varicella, are marginally more common after fingolimod treatment ([@bib0022]; [@bib0120]; [@bib0046]). There may be subtle differences between fingolimod and the other sphingosine-1-phosphate receptor modulators in terms of infections and adverse effects, however it has a relatively long-half-life compared to other agents, which may be relevant if one wants to stop treatment ([@bib0144]; [@bib0145]). A small scale trial of fingolimod has been reported for severe COVID-19 (NCT04280588). Sphingosine-1-phosphate is involved with maintaining the germinal centre and B cell niche ([@bib0033]) and there may be reduced serum immunoglobulin level following fingolimod treatment ([@bib0184]) as such vaccine responses are slightly reduced compared to the interferons ([@bib0116]; [@bib0139]) as occurs with natalizumab ([@bib0116]).

7. Natalizumab as the preferred high-efficacy agent {#sec0009}
===================================================

Currently natalizumab is perceived to be the high-efficacy treatment of choice ([@bib0036]. [Table 1](#tbl0001){ref-type="table"}). Natalizumab, unlike depleting highly-active DMT, is potentially more rapidly reversible using plasma exchange and is not likely to inhibit migration of immune cells into lymphoid tissues and prevent novel immune responses, and as such has no or limited influence on vaccine antibody responses ([@bib0154]; [@bib0082]; [@bib0116]). The value of the use of natalizumab may also be enhanced because it is perceived to inhibit T cell migration into the central nervous system (CNS) ([@bib0174]; [@bib0136]). However, both B cells and importantly monocytes express alpha 4 integrin (CD49d) and thus the antibody directed to CD49d inhibits monocyte binding to vascular cell adhesion molecule one (VCAM-1) ([@bib0174]; [@bib0077]). Importantly, although natalizumab is used to block migration into the inflamed CNS and gut ([@bib0136]), VCAM-1 is expressed in virally-inflamed lungs ([@bib0018]). Therefore, CD49d is likely involved in mononuclear cell diapedesis into the inflamed lung during SARS-CoV-2 infection ([@bib0018]; [@bib0175]). This potential activity is perhaps consistent with increased lung infections in MS following treatment with natalizumab ([@bib0123]). Furthermore, that SARS-CoV-2 is neutrotrophic, ([@bib0004]; [@bib0110], [@bib0069]) suggests that a potential risk of natalizumab treatment is that it blocks viral immunosurveillance of the CNS ([@bib0075]), however this issue is perhaps limited by the extended interval dosing suggested to limit MS activation and reduce the risk of progressive multifocal leukoencephalopathy ([@bib0131]; [@bib0034]). Thus, whilst natalizumab use could potentially be a risk factor for severe COVID-19, it is likely to limit monocyte and T cell damage to the lung and avoiding severe complications.

8. High-efficacy depleting agents are not the same and have distinct COVID-19 risks {#sec0010}
===================================================================================

Based on initial suggestions, immune reconstitution therapies (IRT) were not recommended to be started and ongoing treatment, i.e. additional courses, should be delayed ([Table 1](#tbl0001){ref-type="table"}. [@bib0036]). Autologous HSCT is seen as a high-risk strategy to initiate during the mass-infection stage of COVID-19 pandemic ([Table 1](#tbl0001){ref-type="table"}) and will probably remain so until herd immunity ([@bib0089]) develops. Myeloablative HSCT removes both the adaptive and notably the innate immune systems and it is already well recognised that loss of the neutrophils, monocytes and other elements of the innate immune system increases the risk of mortality from infection, and until the innate and adaptive immune response reconstitutes people will be at risk for some time ([@bib0143]; [@bib0053]; [@bib0130]). However, once reconstituted the capacity to generate new immune responses occurs as seen following vaccination against childhood infections, to replace the lost immunity due to the HSCT procedure ([@bib0017], [@bib0130]). Therefore, there are clear risks from viral infections until the immune system reconstitutes. It is suggested that current licenced IRT, which both deplete T and B cells ([@bib0006]b; [@bib0007]c) carry similar risk ([@bib0036]). However, this does not accommodate the biologies and as such, oral cladribine is dissimilar to alemtuzumab, in terms of its risk for SARS-CoV-2 infection and appears more similar to ocrelizumab in its immunodepletion profile ([Table 2](#tbl0002){ref-type="table"} ).Table 2High efficacy agents are not the same and oral cladribine is more similar to ocrelizumab than alemtuzumab.Table 2:ALEMTUZUMAB^1^CLADRIBINE^7^OCRELIZUMAB^12^PracticalityINFUSION^1^ORAL TABLETS^8^INFUSIONSTEROIDS TO STOP CRS^1^NO STEROIDSSTEROIDS TO STOP CRSHOSPITAL VISITS REQUIRED MONITORING FREQUENT^1^HOSPITAL VISITS NOT REQUIRED MONITORING MINIMAL^8^HOSPITAL VISIT REQUIRED MONITORING MINIMAL^12^DRUG PRESISTANCE \~1 MONTH^1^DRUG PERSISTANCE 1 DAY^8^DRUG PERSISTANCE 5-6 MONTHS^12^Differential Infection RiskEARLY DELETION MONOCYTE^2-4^MONOCYTES IN NORMAL RANGE^9^MONOCYTES IN NORMAL RANGE ^13^NEUTROPHILS IN NORMAL RANGE^3,5^NEURTROPHILS IN NORMAL RANGE (\~10%)^9^NEUTROPHILS IN NORMAL RANGE^12^CD4 DEPLETED (70-90%)^5^CD4 IN NORMAL RANGE (40-50%)^9^CD4 IN NORMAL RANGE (\~2%)^13^CD8 DEPLETED (70-90%)^5^CD8 IN NORMAL RANGE (30-40%)^9^CD8 IN NORMAL RANGE (6-8%)^13^NK CELLS IN NORMAL RANGE (40%)NK CELLS IN NORMAL RANGE (50%)^9^NK CELLS IN NORAML RANGE (\<10%)^13^EfficacyIMMATURE B CELL DEPLETED (3-6 MONTHS)^5^IMMATURE B CELL DEPLETED (6-9 MONTHS)^10^IMMATURE B CELLS DEPLETED PERMANENTLY^13,14^MEMORY B CELLS DEPLETED (\> 1 YEAR)^5^MEMORY B CELLS DEPLETED (\>1YEAR)^10^MEMORY B CELLS DEPLETE PERMANENTLY^13,14^PLASMA CELLS. LOW CD52^5^PLASMA CELLS LOW DEOXYCYTODINE KINASE^11^PLASMA CELLS, NO CD20^12^EARLY INFECTION RISK^1^LIMITED INCREASED RISK^8^LIMITED INCREASED RISK^12^Infection risk(EARLY ANTI-VIRAL REQUIRED)(MAINLY BACTERIAL, INCREASE HERPES)(MAINLY BACTERIAL, INCREASE HERPES)VACCINATION COMPETENT AFTER 6 MONTHS^7^?VACCINATION COMPENTENT and BUT BLUNTED^15^[^2]

8.1. Alemtuzumab {#sec0011}
----------------

This is a CD52-depleting antibody that induces long-lasting and marked (80-90%) depletion of CD4, CD8 T cells and memory B cells ([Table 2](#tbl0002){ref-type="table"}. Baker et al. 2017; [@bib0001]). Alemtuzumab induces long-term disease remission if treated sufficiently early after symptom onset ([@bib0035]. [@bib0066], [@bib0068]b). Two short cycles of treatment give long-term disease remission. Alemtuzumab treatment cycles are generally given at least 12 months apart, but this interval may be extended up to 18 months, which supports the important activity of memory B cells as they, and CD4 T cells, can be depleted for at least this time ([@bib0153], [@bib0066], [@bib0001]). However, alemtuzumab induces transient monocyte depletion and can induce very long-term CD4 and CD8 T cell depletion ([@bib0086]; [@bib0151], [@bib0006]b; [@bib0001]). This influences responses to viral and other infections ([@bib0035]; [@bib0166]) and could thus impact on SARS-CoV-2 outcome. Severe lymphopenia increases the risk of infections and pneumonia ([@bib0160]). Neutropenia after alemtuzumab can be marked and significant, but is unusual ([@bib0008]d). Infection risk is notable following infusion and decreases with time as cellular repopulation occurs ([@bib0020]; [@bib0166]). Alemtuzumab has a relatively short half-life and is cleared from the circulation within about a month ([@bib0095]). Therefore, surviving cells can repopulate in response to infection and given the relatively low dose and delivery over a single week, allows cells escaping elimination to recover. Transitional/immature B cells rapidly repopulate in the relative absence of T cell regulation, possibly related to limited purging of the bone marrow, and can generate anti-drug responses within a month of treatment in 60-83% of people in the virtual absence of peripheral B and T cell ([@bib0006]b; [@bib0012]b). Therefore, perhaps it may be possible to generate anti-viral responses. As such childhood vaccine responses persist and novel vaccine responses are not notably inhibited with alemtuzumab within 6 months of treatment ([@bib0107]). Thus with time people with MS are likely to be able to generate a SARS-CoV-2 response and respond to vaccination. Although the treatment protocol means that few infusion visits are required ([@bib0035]; [@bib0066]), the adverse events, notably the secondary autoimmunities that develop in many people with MS ([@bib0153]; [@bib0066]) means that intensive monitoring is required, compared to ocrelizumab that required essentially no inter-infusion monitoring ([@bib0120]).

8.2. Ocrelizumab {#sec0012}
----------------

This is a CD20-depleting antibody used to treat relapsing and active primary progressive MS ([@bib0064]; [@bib0109]). This depletes peripheral B cells including memory B cells ([@bib0050]). Based on a common mechanism of action ([@bib0005]a), there is an unanswered question of whether ocrelizumab will behave like alemtuzumab and cladribine and provide long-term disease inhibition from a short-term treatment cycle ([Table 2](#tbl0002){ref-type="table"}). Even if it acts as an IRT, based on memory B cell depletion and slow repopulation characteristics ([@bib0119]; [@bib0009]), it may provide some comfort to suggest that delays of 6-12 months may be feasible without MS disease activity reoccurring. The latter is based on information from off-label and phase I/II studies with rituximab in MS ([@bib0013]; [@bib0079]) and phase II extension trial data of ocrelizumab ([@bib0081]; [@bib0011]a). As such retreatment to maintain remission based on repopulation of CD27+ memory B cell population, after 3-4 cycles it seems that doses, at least with rituximab, can be extended to less than once a year ([@bib0113]). Given that ocrelizumab exhibits depletion for a longer duration than rituximab suggests similar or better results can be obtained with rituximab ([@bib0011]a). Although ocrelizumab can deplete CD8 T cells, this is only a relatively mild steady state depletion of only 6-8% depletion of CD8 cells and 1-2% of CD4 T cells and has a minor impact on monocytes ([@bib0059]; [@bib0011]a). Although infections are generally mild following ocrelizumab treatment ([@bib0064]), some viral infections do occur and can be serious and very rarely life threatening ([@bib0064]; [@bib0112]). Importantly, this may become a problem with persistent B cell depletion as that which occurs with ocrelizumab ([@bib0064]). In time this can lead to IgM, IgA and IgG hypogammaglobulinemia that will increase infection risk ([@bib0146]; [@bib0155]). However, a delay in repeated cycles may allow immature cells that provide immunity to new infections to partially regenerate, although this process is slow with ocrelizumab ([@bib0081]; [@bib0011]a), and improve the vaccination response. Consistent with marked B cell depletion, it is apparent that vaccination responses are blunted when initiated 3 months after infusion however, they are not absent ([@bib0142]). As plasma cells do not express CD20, once formed they will not be directly targeted by ocrelizumab ([@bib0132]a). Ofatumumab is a novel subcutaneous CD20-depleting antibody awaiting licencing following a successful phase III programme ([@bib0065]). Ofatumumab dosing shows relatively rapid repopulation of immature B cells compared with slower repopulation with ocrelizumab ([@bib0135]; [@bib0011]a) and thus it remains to be established if the advantage of home injection and reversibility changes the use of anti-CD20 therapies compared to infusions with rituximab and ocrelizumab ([@bib0064], [@bib0065]). Likewise, the real-life extended dosing experiment with rituximab and ocrelizumab is ongoing ([Table 1](#tbl0001){ref-type="table"}). If data captured by registries shows maintained efficacy it is likely that the dosing schedule of ocrelizumab will eventually change on grounds of conveniences, safety and cost-effectiveness, although this will need formal testing ([@bib0113]; [@bib0011]a).

8.3. Cladribine {#sec0013}
---------------

This is an oral small molecule that behaves as an IRT that gives long term-term benefit from short treatment cycles ([@bib0055]; [@bib0056]). This is a B and T cell depletion agent that is eliminated within one day of treatment ([Table 2](#tbl0002){ref-type="table"}) ([@bib0007]c; [@bib0010]; [@bib0071]). Treatment induces depletion via apoptosis rather than cell lysis and thus avoids the need for steroids to manage infusion reactions associated with alemtuzumab and ocrelizumab ([@bib0035]; [@bib0064]). Cladribine can induce comparable long-term memory B cell depletion similar to that observed with alemtuzumab, but without the innate cell and the severe lymphopenia associated with alemtuzumab ([@bib0023]; [@bib0129]). Indeed, the T cell depletion is more modest and CD4 cells are depleted by about 40-50% and CD8 T cells are depleted by 30-40% compared to baseline. In comparison, alemtuzumab results in B and T cell depletion of 80-90% ([@bib0007]c). As such the T cells generally remain within the lower limit of the normal range as do natural killer cells that show modest depletion ([@bib0007]c; [@bib0037]b). The CD19+ B cells recover perhaps slower than post-alemtuzumab, as cladribine probably penetrates and acts more in lymphoid tissues, and the dosing schedule of doses being given a month apart targets any rapidly emerging cells ([@bib0007]c, [@bib0010]). However, B cells probably emerge faster after cladribine compared to ocrelizumab as depleting titres of ocrelizumab remain high for months after infusion ([@bib0054]; [@bib0007]c, [@bib0011]a). Unfortunately, there is no information available concerning the influence of vaccination responses of oral cladribine. Although there is an increased risk of viral infections ([@bib0055]), these are notably less severe than with alemtuzumab ([@bib0120]) associated with the milder immunosuppression induced by cladribine. Thus, oral cladribine, behaves like a chemical CD19/CD20 depleter with some additional T cell activity and is perhaps functionally closer to CD20-depleting antibodies than CD52 depleting antibody. It has the advantage that treatment is not continuous. During the time of self-isolation and shielding to prevent COVID-19 agents such as cladribine may have some merit as it is a high efficacy IRT that can be administered at home, with minimal post-dosing monitoring requirements ([Table 2](#tbl0002){ref-type="table"}).

9. Preliminary experience and personal view of treatment {#sec0014}
========================================================

As analysis of the mechanisms of action of the different DMT coupled with emerging knowledge of the anti-viral and pathogenic mechanisms in COVID-19, suggest that initial fears relating to immunosuppression in MS, have yet to be realised, supporting that found in the SARS epidemics ([@bib0041]; [@bib0058]). The pragmatic approach of examining an individual patient\'s circumstances, their prognostic profile and level of MS disease activity may help guide treatment approaches ([@bib0057]; [@bib0058]). Although these are early days in the initial infection wave of COVID-19, already a number of people with MS have been infected with SAR-CoV-2 with the majority surviving based on early social media and registry data. Although a few people with MS have died they have tended to be older, with more advanced disease and multiple comorbidities. There are now over 360 people with MS and COVID-19 within Italian COVID MS registry with only 5 reported deaths, with only 2 people being treated with DMT and all having comorbidities associated with poor COVID-19 prognosis in the general population. Thus, there does not yet appear evidence that people with MS are at particular risk of severe COVID-19. As such we suggest that risks should be reviewed ([Table 3](#tbl0003){ref-type="table"} ) and advice regarding the risks associated with individual MS-DMT adjusted. Delays in treatment cycles may provide information on the biology of relapsing MS and, if successful may change prescribing habits in the future as there are risk/cost/benefit advantages of reduced dosing frequency. Thus, it will be interesting to determine whether one returns to the current *status quo* after the COVID-19 pandemic wanes or whether extended interval-dosing remains. Likewise, it will be intriguing to determine if real-life data shows that ocrelizumab exhibits IRT-like characteristics whereby long-term benefit can be seen with only short-term treatment cycle as seen with alemtuzumab and oral cladribine. The positive aspect of this unfortunate human experiment created by the SARS-CoV-2 epidemic, is that it will teach us more about the biology of MS and help inform how best to treat this disease and as safely as possibleTable 3Our opinion of altered risks of different MS DMT for COVID-19.Table 3Main attributes of licensed MS DMTs in relation to the COVID-19 pandemic (Version 4.0, 18-April-2020)At risk categoryRankClassTrade NameMode of actionEfficacyClassSafe to start treatmentAdvice regarding treatmentIn the event of COVID-19 infection?Immuosuppression?Response to future SARS-CoV-2 vaccineAttributes and caveatsVery low1Interferon-betaBetaferon, Avonex, Rebif, PlegridyImmunomodulatory (not immunosuppressive), pleiotropic immune effectsModerateMaintenance immunomodulatoryYesContinueContinueNoLikely to be intactHas antiviral properties that may be beneficial in the case of COVID-19Very low2Glatiramer acetateCopaxoneImmunomodulatory (not immunosuppressive), pleiotropic immune effectsModerateMaintenance immunomodulatoryYesContinueContinueNoLikely to be intact-Very low3Cladribine / Alemtuzumab / Mitoxantrone / HSCTsee belowPost-immune reconstitution with normal innate and adaptive immunity (lymphocyte count \> 1000/mm\^3)High / Very highIRTN/AN/AN/ANoLikely to be intactSome patients who may have mitoxantrone or chemotherapy-induced (HSCT) cardiomyopathy may be at increased risk of severe COVID-19Very low4TeriflunomideAubagioDihydro-orotate dehydrogenase inhibitor (reduced de novo pyrimidine synthesis), anti-proliferativeModerate (1st-line) / Moderate to high (2nd-3rd-line)Maintenance immunomodulatoryYesContinueContinuePossible (no well-defined immunosupressive signature)Likely to be intactHas antiviral properties that may be beneficial in the case of COVID-19Low5Dimethyl fumarateTecfideraPleotropic, NRF2 activation, downregulation of NFΚβModerate (2nd-3rd-line) / High (1st-line)Maintenance immunosuppressiveProbablyContinue / Switch if lymphopenicContinueYes, continousLikely to be intactThe risk can only be considered low in paients who do not develop a persistent lymphopenia. Patients with a total lymphocyte count of less than 800/mm\^3 should be considered be at a higher risk of develping complications from COVID19 infection.Low6Natalizumab (EID / extended interval dosing)TysabriAnti-VLA4, selective adhesion molecule inhibitorVery highMaintenance immunosuppressiveYesContinueContinue or miss infusion depending on timingYes, continousLikely to be intactAs COVID-19/SARS-CoV-2 is neurotropic natalizumab will potentially prevent viral clearance from the CNS; this risk is likely to be very low on EID or extended interval dosing. We still have concerns about creating an environment in mucosal surfaces and the gut that may promote prolonged viral shedding; again this risk will be lower with EID.Low7Anti-CD20Ocrelizumab (Ocrevus), Ofatumumab. Rituximab, UblituximabAnti-CD20, B-cell depleterVery highMaintenance immunosuppressiveProbablyRisk assessment - continue or suspend dosingTemporary suspension of dosing depending on timingYes, continousBlunted, particularly to glycoprotein components of a vaccineDoes drop the both CD4+ and CD8+ T-cell populations by up to 20% and this may interact with other factors to affect antiviral responses. Theoretical risk that ocrelizumab and other anti-CD20 therapies may result in prolonged viral shedding.Intermediate8CladribineMavencladDeoxyadenosine (purine) analogue, adenosine deaminase inhibitor, selective T and B cell depletionHigh / Very high (highly-active RMS)IRT (semi-selective)ProbablyRisk assessment - continue or suspend dosingTemporary suspension of dosing depending on timingYes, intermittentPossibly blunted.Only reduces the T-cell compartment by \~50% and has less of an impact on the CD8+ population. Provided total lymphocyte counts are above 500/mm\^3 allowing appropriate antiviral responses should be maintained. Theoretical risk that in the immune depletion phase cladribine may result in prolonged viral shedding.Intermediate9S1P modulatorsFingolimod (Gilenya), Siponimod (Mazent), Ozanimod, PonesimodSelective S1P modulator, prevents egress of lymphocytes from lymph nodesHighMaintenance immunosuppressiveProbablyContinueContinue or temporary suspension of dosingYes, continousBluntedTheoretical risk that S1P modulators may result in prolonged viral shedding. Paradoxically S1P modulators may reduce the severity of COVID-19; fingolimod is currently being trialed.Intermediate10Natalizumab (SID / standard interval dosing)TysabriAnti-VLA4, selective adhesion molecule inhibitorVery highMaintenance immunosuppressiveYesContinue, but consider EIDContinue or miss infusion depending on timingYes, continousLikely to be intactAs COVID-19/SARS-CoV-2 is neurotropic natalizumab will prevent viral clearance from the CNS.Intermediate risk; higher theoretical risk on SID. I have that natalizumab will create an environment in mucosal surfaces and the gut that may promote prolonged viral shedding.High[\*](#tb3fn1){ref-type="table-fn"}11MitoxantroneNovatroneImmune depleter (topoisomerase inhibitor)Very highIRT (non-selective)NoSuspend dosingSuspend dosingYes, intermittentBluntedTheoretical risk that in the immune depletion phase mitoxantrone may result in prolonged viral shedding.High[\*](#tb3fn1){ref-type="table-fn"}12AlemtuzumabLemtradaAnti-CD52, non-selective immune depleterVery highIRT (non-selective)NoSuspend dosingSuspend dosingYes, intermittentBluntedTheoretical risk that in the immune depletion phase alemtuzumab may result in prolonged viral shedding.High[\*](#tb3fn1){ref-type="table-fn"}13HSCT-Immune depletion and haemopoietic stem cell reconstitutionVery highIRT (non-selective)NoSuspend dosingSuspend dosingYes, intermittentBluntedTheoretical risk that in the immune depletion phase HSCT may result in prolonged viral shedding.[^3]
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[^1]: risk refers to acquiring infection during the immunodepletion phase. Post immune reconstitution the risk is low.

    Composite guidelines generated from recommendations to treat MS from the Society of Italian Neurologists (SIN) and the Association of British Neurologists ([@bib0036]).

[^2]: Different characteristics of alemtuzumab, cladribine and ocrelizumab, relevant to efficacy and side-effect potential and their capacity to control MS and exhibit an effective anti-viral immune response. CRS cytokine release syndrome. NK natural killer cell. 1.[@bib0092]. 2. [@bib0151], 3. [@bib0008]d, 4. [@bib0061], 5. [@bib0006]b, 6. [@bib0012]b, 7. [@bib0107], 8. [@bib0106], 9. [@bib0007]c, 10. [@bib0023], 11. [@bib0010], 12. [@bib0117]; 13. [@bib0011]a, 14. [@bib0050], 15. [@bib0142].

[^3]: risk refers to acquiring an infection during the immunodepletion phase ( E.g. rank 11,12,13). Post immune reconstitution the risk is low (rank 3).

    This opinion was formed 18 April 2020.
